Clinical Trial Update: Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing flow rate effects of the Respimat inhaler versus a metered-dose inhaler using Berodual in COPD and asthma patients has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Berodual (ipratropium bromide + fenoterol)
• Respimat inhaler

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive, Asthma | Phase 4 | Status: COMPLETED